Journal article
Osteoclast Inhibitory Lectin, an Immune Cell Product That Is Required for Normal Bone Physiology in Vivo
Vicky Kartsogiannis, Natalie A Sims, Julian MW Quinn, Chi Ly, Mirijana Cipetic, Ingrid J Poulton, Emma C Walker, Hasnawati Saleh, Narelle E McGregor, Morgan E Wallace, Mark J Smyth, T John Martin, Hong Zhou, Kong Wah Ng, Matthew T Gillespie
JOURNAL OF BIOLOGICAL CHEMISTRY | AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC | Published : 2008
Abstract
Osteoclast inhibitory lectin (OCIL or clrb) is a member of the natural killer cell C-type lectins that have a described role mostly in autoimmune cell function. OCIL was originally identified as an osteoblast-derived inhibitor of osteoclast formation in vitro. To determine the physiological function(s) of OCIL, we generated ocil(-/-) mice. These mice appeared healthy and were fertile, with no apparent immune function defect, and phenotypic abnormalities were limited to bone. Histomorphometric analysis revealed a significantly lower tibial trabecular bone volume and trabecular number in the 10- and 16-week-old male ocil(-/-) mice compared with wild type mice. Furthermore, ocil(-/-) mice showe..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
This work was supported by Program Grant 345401 (to M.T.G., T.J.M., N. A.S., and K.W.N.) and Program Grant 454569 (to M.J.S.) from the National Health and Medical Research Council of Australia. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked " advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.